Payment overview · 2025
General Payments
$109.23
6 reported records · 5 companies
Healthcare provider profile · identity verified
David C Daiello, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SARASOTA, FL · NPI 1598738676
Verified facts
What the public records show
CMS Open Payments records show David C Daiello, MD received $109.23 in general payments during 2025 across 6 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.45 | 27.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.87 | 24.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.07 | 17.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.96 | 17.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.88 | 13.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $109.23 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 573 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 550 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 526 | 139 |
| Alprazolam | Alprazolam | 490 | 114 |
| Losartan Potassium | Losartan Potassium | 438 | 117 |
| Lisinopril | Lisinopril | 370 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 312 | 94 |
| Omeprazole | Omeprazole | 295 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 92 |
| Simvastatin | Simvastatin | 265 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 75 |
| Allopurinol | Allopurinol | 228 | 56 |
| Metformin Hcl | Metformin Hcl | 222 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 59 |
| Celecoxib | Celecoxib | 186 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 57 |
| Tramadol Hcl | Tramadol Hcl | 171 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 52 |
| Gabapentin | Gabapentin | 159 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 50 |
| Prednisone | Prednisone | 154 | 106 |
| Valsartan | Valsartan | 152 | 45 |
| Finasteride | Finasteride | 138 | 44 |
| Sertraline Hcl | Sertraline Hcl | 135 | 43 |
| Famotidine | Famotidine | 123 | 50 |
| Meloxicam | Meloxicam | 123 | 38 |
| Montelukast Sodium | Montelukast Sodium | 123 | 31 |
| Temazepam | Temazepam | 118 | 25 |
| Eliquis | Apixaban | 117 | 28 |
| Lorazepam | Lorazepam | 116 | 28 |
| Glimepiride | Glimepiride | 113 | 35 |
| Trazodone Hcl | Trazodone Hcl | 112 | 31 |
| Mirtazapine | Mirtazapine | 107 | 35 |
| Furosemide | Furosemide | 106 | 34 |
| Ozempic | Semaglutide | 103 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 97 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 25 |
| Jardiance | Empagliflozin | 85 | 16 |
| Azithromycin | Azithromycin | 82 | 70 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 25 |
| Potassium Chloride | Potassium Chloride | 78 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 29 |
| Ezetimibe | Ezetimibe | 72 | 23 |
| Synthroid | Levothyroxine Sodium | 72 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 69 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | 20 |
| Estradiol | Estradiol | 57 | 19 |
| Valacyclovir | Valacyclovir Hcl | 57 | 25 |
| Carvedilol | Carvedilol | 56 | 16 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Amoxicillin | Amoxicillin | 53 | 39 |
| Donepezil Hcl | Donepezil Hcl | 53 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 15 |
| Atenolol | Atenolol | 48 | 14 |
| Torsemide | Torsemide | 47 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 12 |
| Mupirocin | Mupirocin | 46 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 15 |
| Spironolactone | Spironolactone | 44 | 17 |
| Diazepam | Diazepam | 43 | 14 |
| Labetalol Hcl | Labetalol Hcl | 42 | 13 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | 11 |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 34 |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 14 |
| Bupropion Xl | Bupropion Hcl | 38 | 12 |
| Azelastine Hcl | Azelastine Hcl | 37 | 24 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 12 |
| Buspirone Hcl | Buspirone Hcl | 35 | 13 |
| Propranolol Hcl | Propranolol Hcl | 35 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 17 |
| Sucralfate | Sucralfate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 24 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 14 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Minoxidil | Minoxidil | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 22 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 23 | 13 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Levofloxacin | Levofloxacin | 18 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 13 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.23 · 6 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ABRYSVO, COMIRNATY, PREVNAR 20, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error